Intracellular Serpin Regulation of Intestinal Cell Necrosis
细胞内丝氨酸蛋白酶抑制剂对肠细胞坏死的调节
基本信息
- 批准号:7729625
- 负责人:
- 金额:$ 41.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinity ChromatographyAnimalsAntithrombinsArchitectureBacteriaBacterial ToxinsBiological ModelsBlood CirculationBrainCaenorhabditis elegansCalpainCationsCell Culture SystemCell DeathCell SurvivalCellsCessation of lifeChemicalsCysteineCytoplasmEpithelial CellsEquilibriumEtiologyEventExhibitsFailureFamilyGastroenteritisGastrointestinal DiseasesGastrointestinal tract structureGenesGeneticGenetic ScreeningGoalsHeartHyperactive behaviorHyperoxiaHypoxiaIn VitroInflammatory Bowel DiseasesInjuryIntestinesInvadedIschemic Bowel DiseaseLearningLiquid ChromatographyLiquid substanceMembraneMolecularMucous body substanceMutagenesisNecrosisNecrotizing EnterocolitisPathologicPathway interactionsPeptide HydrolasesPeptide Signal SequencesPhenotypePlayProtease InhibitorProtein C InhibitorProteolysisRNA InterferenceReactive Oxygen SpeciesRecombinantsRegulationRegulator GenesReperfusion InjuryRespiratory SystemRespiratory tract structureRisk FactorsRoleSeptic ShockSeriesSerineSerpinsShockStimulusSystemTherapeutic UsesTissuesToxinTransgenesUncertain RiskVertebratesbasebiological adaptation to stressfitnessgraft vs host diseasehuman diseasein vivonovelpositional cloningpublic health relevancestressortandem mass spectrometrythermal stress
项目摘要
DESCRIPTION (provided by applicant): Intestinal epithelial cell necrosis is a common pathologic feature of many gastrointestinal disorders including inflammatory bowel disease, infectious gastroenteritis and necrotizing enterocolitis. Although the etiology of intestinal cell necrosis is uncertain, risk factors include anisotonic fluids, toxins, ischemia- reperfusion injury and reactive oxygen species. These stressors perturb peptidase-inhibitor balance, which leads to excessive intracellular proteolysis, loss of membrane integrity, dissolution of sub-cellular architecture and necrotic cell death. The strong association between promiscuous intracellular proteolysis and cell death suggests that peptidase inhibitors serve as necrotic cell death regulators. Extensive searches within the largest family of peptidase inhibitors, the serpins (e.g., antithrombin and 11-antitrypsin), failed to yield candidate regulatory genes. However, this result was not surprising as most serpins are secreted and unlikely to play a regulatory role intracellularly. Recently, we identified a subset of serpins that are abundantly expressed within the cytoplasm of metazoan epithelial cells, including those of the mammalian gastrointestinal tract. Since some of these intracellular serpins (serpinsIC) neutralize lysosomal cysteine and serine peptidases, we hypothesized that they regulate intracellular proteolysis and enhance cell survival. This hypothesis was confirmed by showing that the C. elegans serpinIC, SRP-6, exhibits a pro-survival function by blocking intestinal epithelial cell necrosis. After hypotonic shock, thermal stress, hyperoxia, hypoxia or cation channel hyperactivity; srp-6 nulls underwent a catastrophic series of events culminating in intestinal cell lysosomal disruption, cytoplasmic proteolysis and whole animal death. This newly defined necrotic death phenotype was dependent upon calpains and lysosomal cysteine peptidases, two in vitro targets of SRP-6. SRP-6 provided protection by blocking both the induction of, and the lethal effects from, lysosomal injury. Taken together, we now hypothesize that multiple noxious stimuli converge upon an evolutionarily conserved, peptidase-driven core stress-response pathway that, in the absence of serpinIC regulation, leads to necrotic cell death rather than cell survival. The goal of this proposal is to identify the core molecular components underlying this stress-response pathway by employing powerful unbiased genetic approaches in C. elegans. As a corollary, we will define the intracellular peptidase targets of SRP-6. Finally, comparisons to mammalian systems will determine whether this evolutionarily ancient, serpinIC anti-peptidase defense system regulates intestinal epithelial cell fitness in higher vertebrates. Conservation of this pathway provides the rationale for eventually developing novel anti- necrosis therapeutics using this C. elegans platform. The specific aims are to 1) define the genetic basis of C. elegans intestinal cell necrosis and determine how the stress-response pathway, serpinsIC and lysosomal peptidases determine cell viability, 2) identify the necrotic cell death peptidases regulated by SRP-6 and 3) assess the extent to which mammalian serpinsIC regulate necrotic cell death. PUBLIC HEALTH RELEVANCE: Necrosis is a type of cell death that affects the lining of the intestines and other tissues including the heart and brain. By studying intestinal necrosis in a simpler model system, we will learn how cell death occurs so we can begin to develop new means to treat this very common cause of human disease.
描述(由申请人提供):肠上皮细胞坏死是许多胃肠道疾病的常见病理特征,包括炎症性肠病,感染性胃肠炎和坏死性小肠结肠炎。尽管肠细胞坏死的病因尚不确定,但危险因素包括各向异性液体,毒素,缺血再灌注损伤和活性氧。这些应激源扰动肽酶抑制剂平衡,导致细胞内蛋白水解,膜完整性的丧失,亚细胞结构的溶解和坏死细胞死亡。混杂的细胞内蛋白水解与细胞死亡之间的密切关联表明,肽酶抑制剂是坏死细胞死亡调节剂。在最大的肽酶抑制剂家族中,SERPINS(例如抗凝结蛋白和11-抗抗蛋白酶)的广泛搜索未能产生候选调节基因。但是,这一结果并不奇怪,因为大多数Serpins是分泌的,并且不太可能在细胞内发挥调节作用。最近,我们确定了一部分丝丁蛋白,这些子集在后生细胞的细胞质中大量表达,包括哺乳动物胃肠道的细胞。由于这些细胞内丝丁(Serpinsic)中和溶酶体半胱氨酸和丝氨酸肽酶中和,我们假设它们调节细胞内蛋白水解并增强细胞的存活。通过证明秀丽隐杆线虫SRP-6通过阻止肠上皮细胞坏死,证实了这一假设。低渗性休克,热应力,高氧,缺氧或阳离子通道多动症过度; SRP-6无效发生了一系列灾难性的事件,最终导致肠细胞溶酶体破坏,细胞质蛋白水解和整个动物死亡。这种新定义的坏死死亡表型取决于CALPAIN和溶酶体半胱氨酸肽酶,这是SRP-6的两个体外靶标。 SRP-6通过阻止溶酶体损伤的诱导和致命作用来提供保护。综上所述,我们假设多种有害刺激会在进化保守的肽酶驱动的核心应力反应途径上汇聚,这些途径在没有蛇纹管调节的情况下会导致坏死细胞死亡而不是细胞存活。该提案的目的是通过在秀丽隐杆线虫中采用强大的无偏遗传方法来确定这种应力反应途径的核心分子成分。作为推论,我们将定义SRP-6的细胞内肽酶靶标。最后,与哺乳动物系统的比较将确定这种进化上古老的蛇形抗肽酶防御系统是否调节较高脊椎动物的肠上皮细胞适应性。该途径的保护为最终使用此秀丽隐杆线虫平台开发新型抗坏死疗法提供了理由。具体目的是1)定义秀丽隐杆线虫肠道细胞坏死的遗传基础,并确定应激反应途径如何确定细胞活力,2)确定由SRP-6和3)评估对乳腺胞和培养基的程度来确定坏死性细胞死亡肽酶。公共卫生相关性:坏死是一种细胞死亡,会影响肠道和其他组织在内的内壁,包括心脏和大脑。通过研究更简单的模型系统中的肠道坏死,我们将学习细胞死亡的发生方式,以便我们开始开发新的手段来治疗这种非常普遍的人类疾病原因。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY ARTHUR SILVERMAN其他文献
GARY ARTHUR SILVERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY ARTHUR SILVERMAN', 18)}}的其他基金
Drug Therapies Identified through Modeling AT Deficiency in C Elegans
通过线虫 AT 缺陷建模确定药物治疗
- 批准号:
10197890 - 财政年份:2012
- 资助金额:
$ 41.66万 - 项目类别:
Drug Therapies Identified through Modeling AT Deficiency in C Elegans
通过线虫 AT 缺陷建模确定药物治疗
- 批准号:
10441252 - 财政年份:2012
- 资助金额:
$ 41.66万 - 项目类别:
Drug Therapies Identified through Modeling AT Deficiency in C Elegans
通过线虫 AT 缺陷建模确定药物治疗
- 批准号:
10630352 - 财政年份:2012
- 资助金额:
$ 41.66万 - 项目类别:
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency
针对 Alph-1-抗胰蛋白酶缺乏症的高通量遗传和药物筛选
- 批准号:
8013391 - 财政年份:2010
- 资助金额:
$ 41.66万 - 项目类别:
Intracellular Serpin Regulation of Intestinal Cell Necrosis
细胞内丝氨酸蛋白酶抑制剂对肠细胞坏死的调节
- 批准号:
8321042 - 财政年份:2009
- 资助金额:
$ 41.66万 - 项目类别:
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency
针对 Alph-1-抗胰蛋白酶缺乏症的高通量遗传和药物筛选
- 批准号:
7862206 - 财政年份:2009
- 资助金额:
$ 41.66万 - 项目类别:
相似国自然基金
基于亲和导向-邻近反应的复杂体系天然蛋白固定新方法及色谱评价
- 批准号:22374116
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于亲和色谱策略筛选和挖掘磷酸酶PP2A新型调节剂
- 批准号:22377149
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
基于仿生亲和色谱-质谱策略的肺结核患者血清抗体谱研究
- 批准号:82160027
- 批准年份:2021
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于亲和色谱靶点“钩钓”策略研究补肾活血方抗AGEs诱导神经损伤的作用机制
- 批准号:82104621
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
固定化单构象态受体亲和色谱的建立及止喘灵方平喘功效物质研究
- 批准号:82174088
- 批准年份:2021
- 资助金额:55.00 万元
- 项目类别:面上项目
相似海外基金
Defining the molecular impact of 16p11.2 deletion on reward response in striatal dopamine receptor D1-expressing neurons
定义 16p11.2 缺失对纹状体多巴胺受体 D1 表达神经元奖赏反应的分子影响
- 批准号:
10750328 - 财政年份:2023
- 资助金额:
$ 41.66万 - 项目类别:
Estradiol signaling pathways mediating sex differences in striatal synaptic plasticity
雌二醇信号通路介导纹状体突触可塑性的性别差异
- 批准号:
10607187 - 财政年份:2023
- 资助金额:
$ 41.66万 - 项目类别:
Sigma 2 Receptor (TMEM97): Investigating the Peripheral Role of this Novel Therapeutic Target for Pain
Sigma 2 受体 (TMEM97):研究这种新型疼痛治疗靶点的外周作用
- 批准号:
10607436 - 财政年份:2023
- 资助金额:
$ 41.66万 - 项目类别:
CB1-mediated signaling in developmental ethanol effects
CB1 介导的信号传导对发育乙醇的影响
- 批准号:
10519734 - 财政年份:2023
- 资助金额:
$ 41.66万 - 项目类别:
An immunotherapeutic IgY formulation against norovirus diarrhea
一种针对诺如病毒腹泻的免疫治疗 IgY 制剂
- 批准号:
10693530 - 财政年份:2023
- 资助金额:
$ 41.66万 - 项目类别: